e14654 Background: The incidence of gallbladder carcinoma in Algiers is 1, 4 /105 in male and 2, 8/105 in female, the incidence of bleary tract is 0.3/105 in male and 0.1/105 in female. Since 2002 GC is the gold standard treatment in locally advanced and metastatic gallbladder and biliary tract carcinoma in Algeria. Methods: To accesses overall response, progressive free survival, delay free survival, toxicity profile, clinical benefit of GC in stage III and IV gallbladder and biliary tract carcinoma. 143 patients (pts) were included, 53M/90F,median age 57.1 (32-75) years, 16 pts with biliary tract carcinoma and 138 with gallbladder carcinoma, and received G 1,250 mg/m2 d1 and d8, C 70 mg/m2 d1(d1 = d21), inclusion criteria was proven histologic gallbladder and biliary tract carcinoma stage III or IV, ECOG performance status (less than or equal to) 1, no prior chemotherapy, measurable disease, adequate renal and liver function, good bone marrow reserve. Results: The overall response evaluated after 4 cycles of GC was 30% (9CR, 34PR, 32SD, 68 PD), the overall survival was 9, 3 months the PFS was, 4, 7 months, and the DFS was 14, 7 months. CTC G 3/4 toxicities non hematological toxicity was vomiting in 20%, fatigue in 2%, hematological toxicity was anemia in 5%, neutropenia in 2%, thrombopénia in 1%. The clinical benefit achieved in 72%. Conclusions: GC therapy showed good response, clinical benefit with moderate toxicity in stage III and IV Galbladder and biliary tract carcinoma. No significant financial relationships to disclose.